While there is no clear etiology for AD, distinct biomarkers such as β-amyloid depositions, tau tangles, and brain atrophy have been identified for diagnosing AD and related dementias (ADRDs) that hinder autonomy and negatively impact well-being and sense of purpose in older age.1 The number of Americans with ADRD will continue to increase in the coming years, from an estimated 6.7 million today to a projected 13.8 million by 2060. This evidence concerns the gene MAPT and Alzheimer disease.